A Phase 1, Open-Label, Dose Escalation, and Expansion Study of CUE-102, a Novel WT1-pHLA-IL2-Fc Fusion Protein, in Patients with HLA-A*0201-positive Disease and WT1-positive Recurrent/metastatic Cancers.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined